When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

Malignant pleural mesothelioma (MPM) is an aggressive inflammatory cancer with a poor survival rate. Treatment options are limited at best and drug resistance is common. Thus, there is an urgent need to identify novel therapeutic targets in this disease in order to improve patient outcomes and survi...

Full description

Bibliographic Details
Main Authors: Anne-Marie Baird, David Easty, Monika Jarzabek, Liam Shiels, Alex Soltermann, Sonja Klebe, Stéphane Raeppel, Lauren MacDonagh, Chengguang Wu, Kim Griggs, Michaela B. Kirschner, Bryan Stanfill, Daisuke Nonaka, Chandra M. Goparaju, Bruno Murer, Dean A. Fennell, Dearbhaile M. O'Donnell, Martin P. Barr, Luciano Mutti, Glen Reid, Stephen Finn, Sinead Cuffe, Harvey I. Pass, Isabelle Opitz, Annette T. Byrne, Kenneth J. O'Byrne, Steven G. Gray
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-02-01
Series:Frontiers in Endocrinology
Subjects:
Malignant Pleural Mesothelioma
RON
MET
TAM
RTK
MST1
Online Access:https://www.frontiersin.org/article/10.3389/fendo.2019.00089/full

Internet

https://www.frontiersin.org/article/10.3389/fendo.2019.00089/full

Similar Items